Bionovo gets $1 million grant to study nuclear transport regulation in cancer cells

By Elaine Rigoli

Tampa, Fla., July 12 - Bionovo, Inc. said it has received a $1 million grant from The National Institutes of Health to study a novel mechanism of nuclear transport regulation in cancer cells.

The company will use the fund to study whether the tumor suppressor CC3/TIP30 has a novel cellular function as an inhibitor of nuclear transport.

The company said it has discovered that the highly efficient transport of macromolecules between the cell nucleus and cytoplasm is necessary for tumor growth and metastasis. Normally, the cellular protein CC3 functions to control the rate of this transport, however, its function is disrupted in some tumors.

The company said this anomaly might help tumor cells survive in adverse conditions and remain viable after cytotoxic cancer treatments.

Bionovo is a drug development company based in Emeryville, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.